TABLE 2.
Cardiac-Derived Production | Sinus Rhythm Control (n = 5) | Sustained AF + Vehicle Infusion (n = 5) | Sustained AF + CI-994–Treated (n = 5) |
---|---|---|---|
TNF (pg/h) | 3.2 ± 0.9* | 64 ± 21†‡ | 3.5 ± 1.1* |
IL-1β (pg/h) | 0.1 ± 0.1 | 0.2 ± 0.1 | 0.2 ± 0.1 |
IL-6 (pg/h) | 0.5 ± 0.2*,† | 52 ± 18†,‡ | 2.4 ± 1.2*,‡ |
IL-8 (pg/h) | 0.3 ± 0.1*,† | 28 ± 10†,‡ | 1.9 ± 1.0*,‡ |
IL-10 (pg/h) | 0.2 ± 0.2*,† | 3.3 ± 0.9‡ | 2.9 ± 0.7*,‡ |
Ang-II (ng/h) | 0.1 ± 0.1*,† | 0.3 ± 0.1†,‡ | 0.5 ± 0.1*,‡ |
Resistin (ng/h) | 0.1 ± 0.1 | 0.2 ± 0.1 | 0.3 ± 0.2 |
Adipoq. (μg/h) | 0.3 ± 0.1*,† | 2.1 ± 0.9‡ | 2.0 ± 1.1‡ |
Leptin (ng/h) | 0.1 ± 0.1 | 0.3 ± 0.2 | 0.2 ± 0.1 |
Adipoq., adiponectin; Ang, angiotensin.
P < 0.05 versus AF;
P < 0.05 versus CI-994;
P < 0.05 versus control.